Reports; Results. Each Party shall provide written progress reports on the status of its activities under the Research Plan during the Collaboration, on an Available Target-by-Available Target or Selected Target-by-Selected Target basis, as applicable, including detailed summaries of data associated with such activities and, in the case of EPIZYME, reasonably detailed summaries of data generated in the course of its ongoing platform discovery activities to the extent not previously provided to CELGENE and relevant to the identification or attractiveness for selection of potential Available Targets under Section 2.4.2, at least [**] Business Days in advance of each JRC meeting.
Appears in 2 contracts
Samples: Collaboration and License Agreement (Epizyme, Inc.), Collaboration and License Agreement (Epizyme, Inc.)
Reports; Results. Each Until the end of the Research Term, each Party shall provide written progress reports on the status of its activities under the Research Plan Plans during the Collaboration, on an Available Target-by-Available Target or a Selected Target-by-Selected Target basis, as applicable, including detailed summaries of data associated with such activities and, in the case of EPIZYME, reasonably detailed summaries of data generated in the course of its ongoing platform discovery activities to the extent not previously provided to CELGENE GSK and relevant to the identification or attractiveness for selection of potential Available Targets under Section 2.4.22.2, at least [**] Business Days in advance of each JRC JPT meeting.
Appears in 2 contracts
Samples: Collaboration and License Agreement (Epizyme, Inc.), Collaboration and License Agreement (Epizyme, Inc.)
Reports; Results. Each Subject to Sections 2.3.6 and 2.8.2, each Party shall provide written progress reports on the status of its activities under the Research Plan during the Collaboration, on an Available Target-by-Available Target or Selected Target-by-Selected Target basis, as applicable, including detailed summaries of data associated with such activities and, in the case of EPIZYME, reasonably detailed summaries of data generated in the course of its ongoing platform discovery activities to the extent not previously provided to CELGENE and relevant to the identification or attractiveness for selection of potential Available Targets under Section 2.4.22.9.3, at least [**] Business Days in advance of each JRC meeting.
Appears in 1 contract
Samples: Collaboration and License Agreement (Epizyme, Inc.)